1st FDA on-site inspection of Apextide facility
4th FDA inspection of Sinopep Lianyungang site
About Sinopep
Driving Innovations in Pharmaceuticals
At Sinopep, we are driven to be the trailblazers, advancing peptides, oligonucleotides, and small molecules as lifesaving therapeutic solutions, establishing our leadership in research, development, and manufacturing in pharmaceutical industry. Our unwavering dedication to innovation, pursuit of excellence in execution, and continuous expansion of manufacturing capacities put us in the leading position amongst our peers and competitors.
-
Mission
Driven to save lives and improve human health through innovations.
-
Vision
We strive to be an industry leader and a trusted global partner in drug development to improve quality of life.
-
Core Values
· Integrity & Accountability
· Technology driven, Customer conscious, Urgency
· Open minded, collaborative, and Inclusive
Innovative Solutions for Seamless Collaboration
With our strong commitment to innovation and technology driven mindset, we have established a comprehensive API and drug product supply chain solution enabling our global partners to bring both innovative breakthroughs and cost saving alternatives to patients at any point of the clinical development and commercial stages, in a collaborative and social responsible manner.
-
16years
Of experience -
12,500sqm
State-of-the-art facility -
2,000+
Employees
-
BD Representatives -
Manufacturing Sites -
R&D Centers
-
Hangzhou Yuhang R&D
-
Hangzhou Xiasha R&D
-
Lianyungang R&D
-
Zhejiang Jiande
-
Jiangsu Lianyungang
-
Boston, USA
-
Paris, France
History
-
2024 -
2022
Apextide for oligos founded.
-
2021
IPO in Shanghai Stock Exchange.
-
2019
3rd FDA inspection of Sinopep plant.
-
2017
Merged as Sinopep-Allsino Biopharmaceuticals.
-
2016
2nd FDA inspection of Sinopep plant.
-
2014
1st FDA inspection of Sinopep plant.
-
2009
Sinopep Pharm founded.
-
